Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCZC 54252 hydrochloride is a potent inhibitor of leucine-rich repeat kinase 2 (LRRK2) (IC50 values are 1.28 nM and 1.85 nM for wild-type and G2019S mutant forms of LRRK2 respectively). Attenuates neuronal injury induced by LRRK2-G2019S mutant activity in primary human neurons (EC50 = 1 nM).
分子量 | 541.45 |
公式 | C22H25ClN6O4S.HCl |
储存 | Store at +4°C |
纯度 | ≥98% (HPLC) |
CAS Number | 1784253-05-9 |
PubChem ID | 90488950 |
InChI Key | KWCBHUPLQMUKAF-UHFFFAOYSA-N |
Smiles | ClC1=C(NC3=CC=CC=C3NS(C)(=O)=O)N=C(NC2=C(OC)C=C(N4CCOCC4)C=C2)N=C1.Cl |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Ramsden et al (2011) Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem.Biol. 6 1021 PMID: 21812418
Kramer et al (2012) Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. ACS Chem.Neurosci. 3 151 PMID: 22860184
关键词: CZC 54252 hydrochloride, CZC 54252 hydrochloride supplier, CZC54252, leucine-rich, repeat, kinase, 2, LRRK2, inhibitors, inhibits, potent, neuroprotective, neuronal, injury, parkinson's, parkinsons, 4534, Tocris Bioscience
目前没有该产品的评论。 Be the first to review CZC 54252 hydrochloride and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.